invoX Pharma and Insilico Medicine Enter into Collaboration to Enhance Research and Development using Artificial Intelligence

invoX Pharma and Insilico Medicine Enter into Collaboration to Enhance Research and Development using Artificial Intelligence

23 April, 2024

LONDON, United Kingdom & NEW YORK — April 23, 2024 – invoX Pharma Limited (“invoX”), a research-driven global biopharmaceutical company with an advancing pipeline of innovative products, and Insilico Medicine (“Insilico”), a leading and global clinical stage artificial intelligence (AI)-driven biotechnology company, have entered a new strategic collaboration to combine Insilico’s AI and computational services with invoX’s drug discovery, development and data science capabilities. The aim of the collaboration is to enhance research and development activities for invoX by identifying potential novel indications for pipeline assets in oncology.

The collaboration will utilize Insilico’s target discovery engine, PandaOmics®, in conjunction with invoX’s own drug research and development expertise, to identify new potential indications of interest for existing assets in invoX’s pipeline. These potential indications will then undergo further investigation.

Insilico’s PandaOmics® is an AI-driven biology platform that applies more than 20 predictive models and generative biology models to identify therapeutic targets and biomarkers associated with a given disease.  The system draws from millions of data points to identify the most promising indications and potential drug combinations. It further refines its selection by analyzing attention metrics, discovery trends, relevant data from Key Opinion Leaders and chemistry databases. Apart from target ranking, analysis, and filters, PandaOmics® provides natural language conversations catered to life sciences, as well as knowledge graphs connecting diseases, target genes and potential therapeutic molecules.

“We are very excited about this partnership that allows us to work closely together with experts from Insilico Medicine to expand our digital science and AI capabilities in research and development,” said Ben Toogood, Chief Executive Officer at invoX.  “There is a huge opportunity to enhance drug development through the use of AI and machine learning. We believe that greater use of AI in drug discovery will ultimately lead to more breakthrough innovations in a shorter time, which will enable us to better serve the needs of patients.”

“The collaboration with invoX is a great opportunity for Insilico to collectively advance the state of the art of artificial intelligence itself and apply it in a way that amplifies the creativity of human experts,” said Alex Zhavoronkov, Ph.D., founder and Chief Executive Officer of Insilico Medicine. “To achieve this ambition, artificial intelligence needs to learn from every type of data set that subject matter experts find valuable and that requires the type of close interaction between multiple disciplines we see in this partnership.”

AI models arising from the collaboration will be applied to a range of use cases of which the first two are in execution.  The companies are taking a platform approach to AI where a set of large models is trained for multiple tasks. This will allow new projects and use cases to be initiated on a continuous basis throughout the multi-year collaboration between the companies.

About invoX Pharma

invoX Pharma is a research-driven global biopharmaceutical company using next-generation technology platforms to discover and develop innovative medicines that can change the lives of people around the world. The company aspires to improve people’s lives by creating access to innovative medicines that address their unmet healthcare needs. Incorporated in March 2021, invoX has a core focus on oncology and respiratory therapeutics, with R&D, Clinical Development and Business Development activities in the UK, EU and US.

For further information about invoX Pharma, please visit:

About Insilico Medicine

Insilico Medicine, a leading and global clinical stage biotechnology company powered by generative AI, is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases.

For further information about Insilico Medicine, please visit: